Skip to main content
PMC home page
Infection and Immunity logoLink to Infection and Immunity
. 1981 Dec;34(3):746–750. doi: 10.1128/iai.34.3.746-750.1981

Construction of a potential bivalent vaccine strain: introduction of Shigella sonnei form I antigen genes into the galE Salmonella typhi Ty21a typhoid vaccine strain.

S B Formal, L S Baron, D J Kopecko, O Washington, C Powell, C A Life
PMCID: PMC350934  PMID: 6174449

Abstract

Shigella sonnei, an intestinal pathogen, produces a characteristic form I cell surface antigen now known to be plasmid encoded. We considered that the GalE Salmonella typhi Ty21a oral vaccine strain, highly effective against typhoid, might be modified so as to be protective also against shigellosis due to S. sonnei. The plasmid responsible for form I antigen synthesis was therefore conjugally transferred to the galE S. typhi strain. Serological studies revealed that the derivative strain produces the form I antigen in addition to the normal S. typhi somatic antigens. Testing in mice demonstrated that the derivative form I galE S. typhi strain is protective against both S. sonnei and S. typhi challenges. These data suggest that the galE S. Ty21a oral vaccine strain, which presumably stimulates the local immune system in the intestine, may also serve as a useful carrier for other antigenic determinants to protect against different intestinal infections.

Full text

PDF
746

Images in this article

748Image
on p.748

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. ASHCROFT M. T., RITCHIE J. M., NICHOLSON C. C. CONTROLLED FIELD TRIAL IN BRITISH GUIANA SCHOOL CHILDREN OF HEAT-KILLED-PHENOLIZED AND ACETONE-KILLED LYOPHILIZED TYPHOID VACCINES. Am J Hyg. 1964 Mar;79:196–206. doi: 10.1093/oxfordjournals.aje.a120376. [DOI] [PubMed] [Google Scholar]
  2. DAVIS B. D., MINGIOLI E. S. Mutants of Escherichia coli requiring methionine or vitamin B12. J Bacteriol. 1950 Jul;60(1):17–28. doi: 10.1128/jb.60.1.17-28.1950. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Formal S. B., Kent T. H., Austin S., Labrec E. H. Fluorescent-antibody and histological study of vaccinated and control monkeys challenged with Shigella flexneri. J Bacteriol. 1966 Jun;91(6):2368–2376. doi: 10.1128/jb.91.6.2368-2376.1966. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Formal S. B., Kent T. H., May H. C., Palmer A., Falkow S., LaBrec E. H. Protection of monkeys against experimental shigellosis with a living attenuated oral polyvalent dysentery vaccine. J Bacteriol. 1966 Jul;92(1):17–22. doi: 10.1128/jb.92.1.17-22.1966. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Formal S. B., Maenza R. M., Austin S., LaBrec E. H. Failure of parenteral vaccines to protect monkeys against experimental shigellosis. Proc Soc Exp Biol Med. 1967 Jun;125(2):347–349. doi: 10.3181/00379727-125-32087. [DOI] [PubMed] [Google Scholar]
  6. Germanier R., Füer E. Isolation and characterization of Gal E mutant Ty 21a of Salmonella typhi: a candidate strain for a live, oral typhoid vaccine. J Infect Dis. 1975 May;131(5):553–558. doi: 10.1093/infdis/131.5.553. [DOI] [PubMed] [Google Scholar]
  7. Gilman R. H., Hornick R. B., Woodard W. E., DuPont H. L., Snyder M. J., Levine M. M., Libonati J. P. Evaluation of a UDP-glucose-4-epimeraseless mutant of Salmonella typhi as a liver oral vaccine. J Infect Dis. 1977 Dec;136(6):717–723. doi: 10.1093/infdis/136.6.717. [DOI] [PubMed] [Google Scholar]
  8. HIGGINS A. R., FLOYD T. M., KADER M. A. Studies in shigellosis. III. A controlled evaluation of a monovalent Shigella vaccine in a highly endemic environment. Am J Trop Med Hyg. 1955 Mar;4(2):281–288. [PubMed] [Google Scholar]
  9. Kopecko D. J., Washington O., Formal S. B. Genetic and physical evidence for plasmid control of Shigella sonnei form I cell surface antigen. Infect Immun. 1980 Jul;29(1):207–214. doi: 10.1128/iai.29.1.207-214.1980. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Mel D. M., Terzin A. L., Vuksić L. Studies on vaccination against bacillary dysentery. 3. Effective oral immunization against Shigella flexneri 2a in a field trial. Bull World Health Organ. 1965;32(5):647–655. [PMC free article] [PubMed] [Google Scholar]
  11. Meyers J. A., Sanchez D., Elwell L. P., Falkow S. Simple agarose gel electrophoretic method for the identification and characterization of plasmid deoxyribonucleic acid. J Bacteriol. 1976 Sep;127(3):1529–1537. doi: 10.1128/jb.127.3.1529-1537.1976. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Sansonetti P., David M., Toucas M. Corrélation entre la perte d'ADN plasmidique et le passage de la phase I virulente à la phase II avirulente chez Shigella sonnei. C R Seances Acad Sci D. 1980 Mar 31;290(13):879–882. [PubMed] [Google Scholar]
  13. Wahdan M. H., Serie C., Germanier R., Lackany A., Cerisier Y., Guerin N., Sallam S., Geoffroy P., el Tantawi A. S., Guesry P. A controlled field trial of liver oral typhoid vaccine Ty21a. Bull World Health Organ. 1980;58(3):469–474. [PMC free article] [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES